Tina Tai

Areas of practice

Tina Tai specialises in patent agency, patent invalidation and patent infringement, especially in the pharmaceutical field. Ms. Tai has more than 28 years’ experience as an IP practitioner. She worked with one of China’s largest IP firms for a long time as an executive before joining KWM.

Ms. Tai is one of the most influential figures in IP law in the pharmaceutical and healthcare sectors. She has represented clients in many high-profile patent invalidation and infringement litigation cases, including Viagra® (Sildenafil) and Lipitor® (Atorvastatin) for Pfizer, Brillinta® (Ticagrelor) for AstraZeneca, Xarelto® (Rivaroxaban) for Bayer, Actemra® (Tocilizumab) for Roche/Chugai, Victoza® (Liraglutide) for Novo Nordisk, Entresto® (Valsartan/Sacubitril) and Revolade® (Eltrombopag) for Novartis.

Ms. Tai has been recognised as one of the World’s Leading Patent Practitioners and Leading Lawyer by Managing Intellectual Property (MIP) and IAM 1000 for many years. She was named Eminent Practitioner in the category of intellectual property non-litigation by Chambers Asia Pacific Guide from 2016-2020. She was also selected as one of the first National IP Leading Experts and awarded by China National Intellectual Property Administration as one of the “First Leading Patent Attorneys in China”. She is a regular legal counsel for INTERPAT and the R&D-based Pharmaceutical Association Committee (RDPAC).

Her work highlights include:

1. Represented Pfizer Inc. in the high-profile Viagra® (Sildenafil) case in both invalidation and court proceedings. The case attracted extensive coverage by domestic and overseas media including The Wall Street Journal and was listed as one of the eight “IP Cases of the Year” in 2008.

2. Represented AstraZeneca before Beijing High People’s Court on the patent invalidation case concerning Brillinta® (Ticagrelor). The case was ruled in favor of the client and selected as one of the top 50 IP cases of the year 2018 by the Supreme People’s Court (SPC) and deal of the year 2019 by the China Business Law Journal.

3. Represented Solvay in a patent invalidation matter concerning parameter-defined claims, and successfully maintained the validity of the patent. The decision further provided guidance on how to support parameter defined inventions in the chemistry and pharmaceutical field.

4. Represented Novartis in the Glivec® (Imatinib) case, as well as the patent invalidation and litigation cases of Entresto® (Valsartan/Sacubitril) and Revolade® (Eltrombopag).

Ms. Tai’s representative IP due diligence cases include: 

1. Conducting global IP due diligence in an investment company’s investment in a domestic chemical enterprise. 

2. Conducting patent layout and market analysis in a domestic investment company’s investment in the R&D of a new hepatitis B medicine. 

3. Conducting due diligence including FTO in a domestic investment company’s investment in a domestic ADC pharmaceutical enterprise

In addition, Ms. Tai is also a highly recognised lecturer and project leader in a number of research projects, specifically:

1. She has been a highly recognised lecturer for many years for the “Patent Reexamination and Invalidation”, an induction training course offered by the All-China Patent Attorneys Association for new patent attorneys.

2. She led a team to undertake the soft research project of the CNIPA entitled “Study on the Costs and Strategies for Chinese Applicants Seeking Patent Protections Overseas”.

3. She led a team to undertake the research project of China Intellectual Property Society entitled “Comparative Study on Accurate Calculation of Damages for Patent Infringement”.

4. She led the team for the “Report on the comparative study of Patent Linkage worldwide and implementing proposals in China” (2019)

Work experience

Ms. Tai started her career in 1993. Prior to her joining King & Wood Mallesons in 2019, she worked for China Patent Agent (HK) Ltd. as deputy general manager, responsible for the company’s patent team management and handling of important and complicated cases.

Mr. Tai graduated from Peking University with a bachelor’s degree in applied chemistry and a master’s degree in polymer radiation chemistry. In 2003, she obtained her LL.M degree from the University of London.

Mr. Tai’s working languages are Chinese and English.


This site uses cookies to enhance your experience and to help us improve the site. Please see our Privacy Policy for further information. If you continue without changing your settings, we will assume that you are happy to receive these cookies. You can change your cookie settings at any time.

For more information on which cookies we use then please refer to our Cookie Policy.